FDA Drug · D-0855-2022

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Class II · Terminated

Defective container: loose crimp defect, potential loss of container integrity.

Affected lots / codes — check yours against thisLots: 1142258, 1143196, Exp. 09/24

Recalling firm: Amgen, Inc., Thousand Oaks, CA
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 15,823
Distribution: Nationwide in the USA, Egypt and Lithuania.
Recall initiated: May 2, 2022
Classified: May 9, 2022
Terminated: December 2, 2022
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0855-2022%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

See every recall for this brand: Is Amgen, Inc. recalled? →

Check this brand across all 8 databases →